DOCSLIB.ORG

1145 Volume 238, July-September, 1986 See Moore, D. H., 76

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1145 Volume 238, July-September, 1986 See Moore, D. H., 76 INDEX Volume 238, July-September, 1986 A23187, endothelium-dependent relaxation, agonists, calcium utilization in aorta ride flux across brain membranes, pulmonary vessels, 1055 (rats), 224 763 Abel, P. W., see Moore, D. H., 76 effect of cooling, saphenous and femo- Allen, D. 0., Ahmed, B. and Naseer, K.: Abernathy, D. R., see Todd, E. L., 642 ral veins (dogs), 139 Relationships between cyclic AMP Acara, M. A., see Ferniola, P. C., 912 pressor responses and receptor reserve, levels and lipolysis in fat cells after Acetaminophen calcium antagonists (rats), 89 isoproterenol and forskolin stirnula- conjugation, reduced hepatic energy state response coupling, saphenous and fern- tion, 659 effects (rats), 463 oral veins (dogs), 131 Ally! alcohol, hepatotoxicity due to, liver hepatotoxicity, glutathione role in pre- vasoconstriction, pulmonary circula- lobule (rats), 1132, 1138 vention, N-acetyl-L-cysteine (mice), tion (dogs), 217 Ambrose,. F., see Rinehart, R. K., 178 54 apha-2 Amiloride, prostatic secretion, drug-modi- pharmacokinetic studies, disposition, ma- effect of cooling, saphenous and femo- fled ion transport (dogs), 26 ternal-placental-fetal unit (sheep), ral veins (dogs), 139 Amino acids 198 response coupling, saphenous and fern- enzyme inactivation, retina vs. brain Acetazolamide oral veins (dogs), 131 (rats), 508 bone resorption and (mice), 778 studies that question the existence of, excitatory, striatum, phencyclidine effects renal sodium/potassium-ATPase trans- tail arteries (rats), 267 (rats), 938 port rate, transcellular NaC1 reab- vasoconstriction, pulmonary circula- -y-Aminobutynic acid sorption (dogs), 327 tion (dogs), 217 chloride flux, barbiturate alteration of, Acetazolamine, prostatic secretion, drug- alpha agonists brain membrane (mice), 763 modified ion transport (dogs), 26 antagonists, antihypertensive effects enzyme inactivation, retina vs. brain Acetylcholine (rats), 372 (rats), 508 dopamine interactions, release modula- control of microvascular reserve, myo- Aminoglycoside, nephrotoxicity, gentamicin tory receptors (rabbits), 437 cardiurn (rabbits), 868 transport, 1071 endothelium-dependent relaxation, pad- mechanical rsponses, airway smooth Aminopyrine N-demethylase, hepatic mon- monary vessels, 1055 muscle (dogs), 679 ooxygenase system, persistent de- muscarinic receptors, brain, N-methyl- radioligand selectivity, quantitative fects, phenytoin (rats), 68 scopolamine binding to (rats), 554 analysis, 46 Aniiodarone, induced biotransformation, release, presynaptic apha-1 receptor sympathetic transmission, heart (dogs), ventricular refractory periods (rats), modulation of, atria (rats), 612 334 307 N-Acetyl-L-cysteine, acetaminophen-in- thrombin-stirnulated contraction and, Amphetamine, mydniasis, mechanism duced hepatotoxicity, glutathione arteries (rabbits), 954 (rats), 788 role in prevention (mice), 54 alpha-i and apha-2, differential inhibi- Arnygdala, antidepressant drugs injected Adenosine analogs, vasodilator effects, tion by nitroglycerin, saphenous vein into, behavioral responses and (rats), spontaneous hypertension (rats), 954 (dogs), 515 758 Adenosine 3’-phosphate 5’phosphoaulfate, beta-2, cardiovascular responsiveness, Analgesia, dynorphin A, administered in- hepatic energy state, conjugation and sympathetic activation after api- trathecally, spinal cord (rats), 833 (rats), 457 nephnine (rats), 148 Anesthetics Adenosine tniphosphatase, renal sodium Adrenocorticotropin, desensitization, stirn- antihistamines and, excess tachycardia and potassium transport rate, trans- ulatory effects of nicotine (rats), 486 (dogs), 367 cellular sodium chloride reabsorption Aging, coronary arteries, transrnural electri- nitrous oxide, effect on embryos (rats), (dogs), 327 cal stimulation, catecholarnines 985 Adenylate cyclase (dogs), 319 Angiotensin, enzyme conversion inhibitor, adrenergic receptors to, atria (dogs), 886 Ahrned, B., see Allen, D. 0., 659 lungs (rabbits), 14 forskolin-stimulated, serotonin inhibi- Airway Angiotension antagonist, sympathetic vaso- tion, hippocampal membranes smooth muscle constriction and renin secretion, (guinea pigs, rats), 248 phosphatidylinositol response, cholin- presser responses, thyrotropin-re- Adkinson, N. F., Jr., see Peters, S. P, 8 ergic agonists (cattle), 273 leasing hormone (rats), 232 Adler, M. W., see Klemfuss, H., 788 relaxation, verapamil, isoproterenol Aniline, metabolism and toxicity, hemolytic Adrenergic nerves, cardiac acceleration, and prostaglandin E, (dogs), 76 anemia (rats), 1045 pharmacological analysis (rats, Akera, T., see Berlin, J. R., 632 Anions, exchange, bumetanide inhibition of, guinea pigs), 713 Albers, L. J., see Hess, E. J., 846 renal thick limbs (mice), 407 Adrenoceptors Alcohol, central nervous system depressant, Ansari, A. F., see A!kadhi, K. A., 547 apha long- and short-sleep (mice), 1028 Antagonists, see specific type CH-38083 effects (guinea pigs, rats, Aleen, A., see Cicero, T. J., 1063 Antiarrhythmic agents mice), 701 A!kadhi, K. A., Sabouni, M. H., Ansari, A. amiodarone, induced transformation, maintenance of neurogenic tone and, F. and Lokhandwala, M. F.: Activa- ventricular refractory period (rats), hindlimb vasculature (dogs), 599 tion of DA1 receptors by dopamine or 307 mechanical responses, airway smooth fenoldopam increases cyclic AMP dantrolene sodium, isolated sinoatrial and muscle (dogs), 679 levels in the renal artery but not in atrioventricular nodes, ischemia modulation of nociceptive jaw-opening the superior cervical ganglion of the model (rabbits, dogs), 206 reflex (rats, rabbits), 576 rat, 547 Anticonvulsants vascular smooth muscle, Schild plot Allan, A. M. and Harris R. A.: Anesthetic action, repetitive firing in central neurons limitations, 237 and convulsant barbiturates alter ‘y- (rats), 727 1 aminobutynic acid-stimulated chlo- behavioral toxicity, chronic ethosuximide 1145 1146 Index Vol. 238 and sodium valproate, epilepsy (ba- dilator effects, spontaneous hyper- Bay K 8644, dihydropyridine derivatives boons), 32 tension (rats), 954 and, vascular and cardiac effects modulation of behavioral effects, external Artaud, F., see Bourgoin, S., 360 (rabbits, guinea pigs), 670 discriminative stimulus (pigeons), Artery Begaud, B., see Chel!y, J. E., 665 529 coronary, age-dependent changes, cats- Behavior phenytoin, hepatic monooxygenase sys- cholamines (dogs), 319 anticonvulsant drug effects, modulation tern, persistent defects (rats), 68 smooth muscle and endothelium, musca- by external discriminative stimulus Antidepressant drugs, injected into amyg- rinic receptors, characterization (rab- (pigeons), 529 dala, behavioral responses and (rats), bits), 100 rotational, supersensitivity, apomorphine 758 tail, apha-2 adrenoceptors, question of (mice), 242 Antidiuretic hormone existence (rats), 267 schedule-controlled, benzodiazepine-like inhibition of transepithelial water flux, 2-Arylpropionic acid, enantioselective dis- drugs (monkeys), 522 urinary bladder (toad), 401 position, nonsteroidal anti-inflam- toxicity, chronic ethosuximide and so- prostaglandins and, water handling, matory drugs (rabbits), 280, 288 chum valproate, epilepsy (baboons), renal, 653 Atchison, W. D., Joshi, U. and Thornburg, 32 Antiepileptic agents, behavioral toxicity, J. E.: Irreversible suppression of cal- Belinsky, S. A., Badr, M. Z., Kauffman, F. chronic ethosuximide and sodium cium entry into nerve terminals by C. and Thurman, R. G.: Mechanism valproate (baboons), 32 methylmercury, 618 of hepatotoxicity in peniportal re- Antihistamines, local anesthetics and, ex- Atkinson, T., see Electnicwala, A., 254 gions of the liver lobule due to allyl cess tachycardia (dogs), 367 Atnia alcohol: Studies on thio!s and energy Antihypertensive agents, profile and phar- acety!choline release, presynaptic alpha-i status, 1132 macology (rats), 473 receptor modulation of (rats), 612 Belinsky, S. A., see Bath, M. Z., 1138 Anti-inflammatory drugs beta adrenergic subtypes in (dogs), 886 Belis, J. A., see Longhurst, P. A., 773 2-arylpropionic acid, enantioselective dis- quinidine and digoxin, pharmacodynamic Benet, L. Z., see Wang, L. H., 198 position (rabbits), 280, 288 interactions between (guinea pigs), Benza!konium chloride, jejunal contractil- tenoxicam, acceleration of elimination, 632 ity, after chronic ablation, myentenic cholestyramine (dogs), 295 right, transmural nerve stimulation plexus (rats), 372 Antipsychotic drugs, depolarization block (guinea pigs, rats), 713 Benzodiazepines induction, midbrain dopamine neu- Atnial natriuretic peptide, tubular site of behavioral effects (monkeys), 522 rons (rats), 1092 action, anesthesia and (dogs), 707 interactions, central thyroid-releasing Antonaccio, M. J., High, J., DeForrest, J. Atropine hormone binding sites (rats), 178 M. and Sybertz, E.: Antihypertensive antihistamines and local anesthetics, ax- peripheral-type, downregulation of [3HJ effects of 12 beta adrenoceptor antag- cess tachycardia (dogs), 367 R05-4864 binding sites, 855 onists in conscious spontaneously hy- gastrointestinal effects of hyperserotoni- receptors, see Receptors nemia and 536 pertensive rats: Relationship to (dogs), Benzoflavones, activity, placental tissues Autoradiography changes in plasma renin activity, (rats), 1108 benzodiazepine receptors, regulation, im- heart rate and sympathetic nerve Bepridil, stimulation, cardiac myofilaments aging (rats), 739 function, 378 (pigs), 502 localization of delta opioid receptors, Anxiolytic drugs, behavioral studies (pi- Bergen, J. and Kroeger, E. A.: Adreno- brain (rats), 720 geons), 1009 ceptor-mediated
Load more

Recommended publications
  • Characterisation of the Α1b-Adrenoceptor by Modeling, Dynamics and Virtual Screening Kapil Jain B.Pharm, M.S.(Pharm.)
    Characterisation of the α1B-Adrenoceptor by Modeling, Dynamics and Virtual Screening Kapil Jain B.Pharm, M.S.(Pharm.) A Thesis submitted for the degree of Master of Philosophy at The University of Queensland in 2018 Institute for Molecular Bioscience 0 Abstract G protein-coupled receptors (GPCRs) are the largest druggable class of proteins yet relatively little is known about the mechanism by which agonist binding induces the conformational changes necessary for G protein activation and intracellular signaling. Recently, the Kobilka group has shown that agonists, neutral antagonists and inverse agonists stabilise distinct extracellular surface (ECS) conformations of the β2-adrenergic receptor (AR) opening up new possibilities for allosteric drug targeting at GPCRs. The goal of this project is to extend these studies to define how the ECS conformation of the α1B-AR changes during agonist binding and develop an understanding of ligand entry and exit mechanisms that may help in the design of specific ligands with higher selectivity, efficacy and longer duration of action. Two parallel approaches were initiated to identify likely functional residues. The role of residues lining the primary binding site were predicted by online web server (Q-Site Finder) while secondary binding sites residues were predicted from molecular dynamics (MD) simulations. Predicted functionally significant residues were mutated and their function was established using FLIPR, radioligand and saturation binding assays. Despite the α1B-AR being pursued as a drug target for over last few decades, few specific agonists and antagonists are known to date. In an attempt to address this gap, we pursued ligand-based approach to find potential new leads.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Defic
    M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Deficits in Sprague–Dawley and Wistar Rats Geoffrey B. Varty, Ph.D., Vaishali P. Bakshi, Ph.D., and Mark A. Geyer, Ph.D. a In a recent study using Wistar rats, the serotonergic 5-HT2 1 receptor agonist cirazoline disrupts PPI. As risperidone a receptor antagonists ketanserin and risperidone reduced the and M100907 have affinity at the 1 receptor, a final study disruptive effects of the noncompetitive N-methyl-D- examined whether M100907 would block the effects of aspartate (NMDA) antagonist dizocilpine on prepulse cirazoline on PPI. Risperidone partially, but inhibition (PPI), suggesting that there is an interaction nonsignificantly, reduced the effects of dizocilpine in Wistar between serotonin and glutamate in the modulation of PPI. rats, although this effect was smaller than previously In contrast, studies using the noncompetitive NMDA reported. Consistent with previous studies, risperidone did antagonist phencyclidine (PCP) in Sprague–Dawley rats not alter the effects of dizocilpine in Sprague–Dawley rats. found no effect with 5-HT2 antagonists. To test the hypothesis Most importantly, M100907 pretreatment fully blocked the that strain differences might explain the discrepancy in effect of dizocilpine in both strains; whereas SDZ SER 082 these findings, risperidone was tested for its ability to had no effect. M100907 had no influence on PPI by itself reduce the PPI-disruptive effects of dizocilpine in Wistar and did not reduce the effects of cirazoline on PPI. These and Sprague–Dawley rats. Furthermore, to determine studies confirm the suggestion that serotonin and glutamate which serotonergic receptor subtype may mediate this effect, interact in modulating PPI and indicate that the 5-HT2A the 5-HT2A receptor antagonist M100907 (formerly MDL receptor subtype mediates this interaction.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • 6. Literaturverzeichnis 6
    Seite 148 6. Literaturverzeichnis 6. Literaturverzeichnis Aboud R., Shafii M. & Docherty J.R. (1993). Investigation of the subtypes of α1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen. Br. J. Pharmacol., 109, 80-87. Aghajanian G.K. & Marek G.J. (1999). Serotonin and hallucinogens. Neuropsychopharmacology, 21 (Suppl.), 16S-23S. Ahlquist R.P. (1948). A study of the adrenergic receptors. Am. J. Physiol.. 153, 585-600. Akin D. & Gurdal H. (2002). Involvement of 5-HT1B and 5-HT1D receptors in sumatriptan mediated vasocontractile response in rabbit common carotid artery. Br. J. Pharmacol., 136, 177-182. Ali A., Cheng H.Y., Ting K.N. & Wilson V.G. (1998). Rilmenidine reveals differences in the pharmacological characteristics of prejunctional α2-adrenoceptors in the guinea-pig, rat and pig. Br. J. Pharmacol., 125, 127-135. Almaula N., Ebersole B.J., Ballesteros J.A., Weinstein H. & Sealfon S.C. (1996a). Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5- hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. Mol. Pharmacol., 50, 34-42. Almaula N., Ebersole B.J., Zhang D., Weinstein H. & Sealfon S.C. (1996b). Mapping the binding site pocket of the 3.36(159) serotonin 5-Hydroxytryptamine2A receptor. Ser provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J. Biol. Chem., 271, 14672-14675. Amobi N., Guillebaud J., Coker C., Mulvin D. & Smith I.C.H. (1999). Functional characterization of α1-adrenoceptor subtypes in longitudinal and circular muscle of human vas deferens.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Clozapine and Olanzapine, but Not Haloperidol, Suppress Serotonin Efflux in the Medial Prefrontal Cortex Elicited by Phencyclidi
    ARTICLE International Journal of Neuropsychopharmacology (2006), 9, 565–573. Copyright f 2005 CINP doi:10.1017/S1461145705005900 Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine Merce` Amargo´s-Bosch, Xavier Lo´pez-Gil, Francesc Artigas and Albert Adell Department of Neurochemistry, Institut d’Investigacions Biome`diques de Barcelona, CSIC (IDIBAPS), 08036 Barcelona, Spain Abstract N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP) and ketamine can evoke psychotic symptoms in normal individuals and schizophrenic patients. Here, we have examined the effects of PCP (5 mg/kg) and ketamine (25 mg/kg) on the efflux of serotonin (5-HT) in the medial pre- frontal cortex (mPFC) and their possible blockade by the antipsychotics, clozapine, olanzapine and halo- peridol, as well as ritanserin (5-HT2A/2C receptor antagonist) and prazosin (a1-adrenoceptor antagonist). The systemic administration, but not the local perfusion, of the two NMDA receptor antagonists markedly increased the efflux of 5-HT in the mPFC. The atypical antipsychotics clozapine (1 mg/kg) and olanzapine (1 mg/kg), and prazosin (0.3 mg/kg), but not the classical antipsychotic haloperidol (1 mg/kg), reversed the PCP- and ketamine-induced increase in 5-HT efflux. Ritanserin (5 mg/kg) was able to reverse only the effect of PCP. These findings indicate that an increased serotonergic transmission in the mPFC is a functional consequence of NMDA receptor hypofunction and this effect is blocked by atypical antipsychotic drugs. Received 24 March 2005; Reviewed 18 April 2005; Revised 15 June 2005; Accepted 15 June 2005; First published online 15 August 2005 Key words: Clozapine, haloperidol, ketamine, phencyclidine, serotonin.
    [Show full text]
  • Bradycardic Effects of AQ-A 39 (Falipamil) in Situ and in Isolated, Blood-Perfused Dog Hearts Comparison with Alinidine and Verapamil
    Bradycardic Effects of AQ-A 39 (Falipamil) in Situ and in Isolated, Blood-Perfused Dog Hearts Comparison with Alinidine and Verapamil Yasuhiro OGIWARA, M.D., Yasuyuki FURUKAWA, M.D., Kunio AKAHANE, M.D., Masayuki HANIUDA, M.D., and Shigetoshi CHIBA, M.D. SUMMARY The cardiovascular effects of a specific bradycardic agent, AQ-A 39, were investigated in intact donor dogs and isolated and cross-perfused dog heart preparations. Intravenous administration of AQ-A 39 (10- 1000ƒÊg/kg) to the donor dog caused a dose-dependent heart rate de- crease in the donor dog and a decreased atrial rate in the isolated atrium perfused by the donor's blood. The arterial blood pressure of the donor dog and contractile force of the atrial preparation were unchanged or slightly decreased. The direct injection of AQ-A 39 (1-300ƒÊg) into the sinus node artery of the isolated atrium caused dose-dependent negative chronotropic and slight, transient positive inotropic responses. Alinidine and verapamil caused marked negative chronotropic and inotropic re- sponses. The negative chronotropic effect of AQ-A 39 was not modified by atropine. However, it was enhanced slightly but significantly by pro- pranolol, indicating that AQ-A 39-induced bradycardia was antagonized partly by beta-adrenoceptor function. These results confirmed that AQ-A 39 selectively reduced sinus rate by a direct action on the sinus node. Furthermore, the potency of the bradycardic action, compared with the decrease in contractility, was greater than for alinidine or verapamil. AQ-A 39 (300ƒÊg) tended to depress norepinephrine (NE)-induced posi- tive chronotropic but not inotropic effects in isolated atria.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]